24812 Federal Register / Vol. 63, No. 86 /Tuesday, May 5, 1998 / Notices

Charles W. Gollmar,

Acting Associate Director for Policy Planning

and Evaluation, Centers for Disease Control

and Prevention (CDC).

[FR Doc. 98–11823 Filed 5–4–98; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Centers for Disease Control and

Prevention

Safety and Occupational Health Study

Section NIOSH Meeting

In accordance with section 10(a)(2) of

the Federal Advisory Committee Act

(Pub. L. 92–463), the Centers for Disease

Control and Prevention (CDC)

announces the following committee

meeting:

Name: Safety and Occupational Health

Study Section, National Institute for

Occupational Safety and Health (NIOSH).

Times and dates: 8 a.m.–5:30 p.m., June

18, 1998. 8 a.m.–5:30 p.m., June 19, 1998.

Place: Embassy Suites Hotel, 1900

Diagonal Road, Alexandria, Virginia 22314.

Status: Open 8 a.m.–8:30 a.m., June 18,

1998; Closed 8:30 a.m.–5:30 p.m., June 18,

1998; Closed 8 a.m.–5:30 p.m., June 19, 1998.

Purpose: The Safety and Occupational

Health Study Section will review, discuss,

and evaluate grant application(s) in response

to the Institute’s standard grants review and

funding cycles pertaining to research issues

in occupational safety and health and allied

areas.

It is the intent of NIOSH to support broadbased research endeavors in keeping with the

Institute’s program goals which will lead to

improved understanding and appreciation for

the magnitude of the aggregate health burden

associated with occupational injuries and

illnesses, as well as to support more focused

research projects which will lead to

improvements in the delivery of occupational

safety and health services and the prevention

of work-related injury and illness. It is

anticipated that research funded will

promote these program goals.

Matters to be discussed: The meeting will

convene in open session from 8–8:30 a.m., on

June 18, 1998, to address matters related to

the conduct of Study Section business. The

remainder of the meeting will proceed in

closed session. The purpose of the closed

sessions is for the Safety and Occupational

Health Study Section to consider safety and

occupational health related grant

applications. These portions of the meeting

will be closed to the public in accordance

with provisions set forth in section 552(c) (4)

and (6), title 5 U.S.C., and the Determination

of the Associate Director for Management and

Operations, CDC, pursuant to Public Law 92–

463.

Agenda items are subject to change as

priorities dictate.

Contact person for more information:

Pervis C. Major, Ph.D., Scientific Review

Administrator, Office of Extramural

Coordination and Special Projects, Office of

the Director, NIOSH, 1095 Willowdale Road,

Morgantown, West Virginia 26505.

Telephone 304/285–5979.

Dated: April 28, 1998.

Nancy C. Hirsch,

Acting Director, Management Analysis and

Services Office, Centers for Disease Control

and Prevention (CDC).

[FR Doc. 98–11820 Filed 5–4–98; 8:45 am]

BILLING CODE 4163–19–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Food and Drug Administration

[Docket No. 96F–0348]

MacMillan Bloedel, Ltd.; Withdrawal of

Food Additive Petition

AGENCY: Food and Drug Administration,

HHS.

ACTION: Notice.

SUMMARY: The Food and Drug

Administration (FDA) is announcing the

withdrawal, without prejudice to a

future filing, of a food additive petition

(FAP 6B4520) proposing that the food

additive regulations be amended to

provide for the safe use of ethylene

glycol as a component of a pulp

bleaching medium used in the

manufacture of paper and paperboard

intended for use in contact with food.

FOR FURTHER INFORMATION CONTACT:

Andrew J. Zajac, Center for Food Safety

and Applied Nutrition (HFS–215), Food

and Drug Administration, 200 C St. SW.,

Washington, DC 20204, 202–418–3095.

SUPPLEMENTARY INFORMATION: In a notice

published in the Federal Register of

October 7, 1996 (61 FR 52454), FDA

announced that a food additive petition

(FAP 6B4520) had been filed by

MacMillan Bloedel, Ltd., c/o Camplong

& Associates, Inc., P.O. Box 238,

Schomberg, ON L0G 1T0, Canada. The

petition proposed to amend the food

additive regulations in § 176.170

Components of paper and paperboard

in contact with aqueous and fatty foods

(21 CFR 176.170) to provide for the safe

use of ethylene glycol as a pulp

bleaching agent for paper and

paperboard intended for use in contact

with food. Upon further review, FDA

has determined that the petition

proposed the use of ethylene glycol as

a component of a pulp bleaching

medium used in the manufacture of

food-contact paper and paperboard.

MacMillan Bloedel, Ltd., has now

withdrawn the petition without

prejudice to a future filing (21 CFR

171.7).

Dated: April 10, 1998.

Laura M. Tarantino,

Acting Director, Office of Premarket

Approval, Center for Food Safety and Applied

Nutrition.

[FR Doc. 98–11805 Filed 5–4–98; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Food and Drug Administration

Vaccines and Related Biological

Products Advisory Committee; Notice

of Meeting

AGENCY: Food and Drug Administration,

HHS.

ACTION: Notice.

This notice announces a forthcoming

meeting of a public advisory committee

of the Food and Drug Administration

(FDA). At least one portion of the

meeting may be closed to the public.

Name of Committee: Vaccines and

Related Biological Products Advisory

Committee.

General Function of the Committee:

To provide advice and

recommendations to the agency on FDA

regulatory issues.

Date and Time: The meeting will be

held on May 26 and 27, 1998, 8 a.m. to

5:45 p.m.

Location: Holiday Inn, Versailles

Ballrooms I and II, 8120 Wisconsin

Ave., Bethesda, MD.

Contact Person: Nancy T. Cherry or

Denise H. Royster, Center for Biologics

Evaluation and Research (HFM–21),

Food and Drug Administration, 1401

Rockville Pike, Rockville, MD 20852,

301–827–0314, or FDA Advisory

Committee Information Line, 1–800–

741–8138 (301–443–0572 in the

Washington, DC area), code 12391.

Please call the Information Line for upto-date information on this meeting.

Agenda: The committee will: (1)

Consider the safety and efficacy of a

new vaccine from SmithKline for the

prevention of Lyme disease; (2) consider

the safety and efficacy of a live, oral,

attenuated vaccine for the prevention of

cholera; and (3) discuss issues relating

to the potential inclusion of a boxed

warning on the package insert for live

polio virus vaccine.

Procedure: On May 26 and 27, 1998,

from 9 a.m. to 5:45 p.m., the meeting is

open to the public. Interested persons

may present data, information, or views,

orally or in writing, on issues pending

before the committee. Written

submissions may be made to the contact

person by May 19, 1998. Oral